The rapid development of mRNA COVID-19 vaccines is an unprecedented success for medicine and it heralds a new era in the development of vaccines for other (infectious) diseases.
The benefits and utility of this technology became quickly clear amongst academic research groups, public health as well as government agencies. Extensive clinical trials have confirmed the safety and efficacy of mRNA vaccines, and the principles of this technology have the potential to be applied to a wide range of other (infectious) diseases.
This might revolutionize the prevention and treatment of, for instance, cancer and many high priority infectious diseases (e.g., malaria, tuberculosis, and HIV), where other vaccine platforms have not been successful.
Compared to other vaccine platforms, mRNA vaccines show robust immune responses and have the potential to be designed and manufactured rapidly. However, there are still questions to be answered, for example regarding the durability of immunity provided.
The advances of mRNA vaccines come together with educational needs to comprehend technology, properties, benefits/limitations, applications to other diseases, and recent clinical data.
This program will encompass the pathway from target discovery and validation to (early) clinical development and use; and include mRNA modifications and delivery methods.
More information can be found at